Patient centricity is on the rise, and oncology trials have led the charge in that department. It could be said that decentralization is necessary for oncology trials because of the burden it removes from your patients. That’s not to say a fully virtual model will be feasible for oncology trials, but decreasing patient burden is something that could be viewed as necessary to conduct a successful oncology study. When less than 5% of cancer patients participate in clinical research, it’s imperative to engage the right patients throughout the process, and we do that by bringing the trial into their homes.
Decentralized clinical trials have proven to decrease patient dropout rates and increase patient engagement, two critical factors for oncology. With the rise of immuno-oncology and precision medicine, the patient pools continue to get smaller and smaller, and drop-out rates can make or break a clinical trial.
One way to decrease patient drop out is through the informed consent process. Many patients have reported “unclear expectations” as a primary reason for dropping out of clinical trials following only behind “inconvenience.” eConsent can address both issues simultaneously. An electronic consenting process puts the patient in control and empowers them to make informed decisions. The addition of rich media in the consenting process increases patient understanding of expectations, thus reducing dropout rates for that reason. The convenience of eConsent is that it can be done in-clinic or remote, allowing sick patients to remain at home thus reducing the patient burden, and increasing your patient pool.
Patient engagement is another key element to consider. While the consenting process can become more engaging through rich media via electronic collection, it’s only a small piece of the puzzle. Patients are tasked with routine reporting, and traveling to a site for data collection is not always feasible for really sick patients, and perceived as inconvenient for others. Electronic patient-reported outcomes (ePRO) can be enabled on the patients’ preferred device, allowing them to report from anywhere at any time.
Clinicians can utilize direct data capture (DDC) to report directly about the patient’s condition online or offline and have the data sync directly back to their EDC at the push of a button in real-time. This type of data collection can be done in a patient’s home, reducing patient burden, and can eliminate source data verification – saving you time and accelerating your study timelines. When less than 20% of oncology studies remain on-time, in other words failing to meet initial expectations, reducing study timelines where you can is crucial.
At the heart of a decentralized trial is your EDC. When your primary goal is to get treatments to the patients who need them, getting your study started quickly can make all the difference. The industry average timeline for study build is twelve weeks, but with Medrio we can get you started in less than three (we’ve even achieved FPI in only 7 days!).
An electronic data capture system doesn’t have to be complicated or complex to handle a complex study. Our EDC offers simplicity without compromise. We put you in the driver’s seat so that you have total control over your data. Our EDC is not only secure and compliant, but also affordable with no hidden fees, and it seamlessly integrates with our eConsent, ePRO, and DDC solutions.